Prana to Present at the B. Riley FBR China Healthcare Investment & Partnering Symposium in Hangzhou, China

MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – March 16 2018: Prana Biotechnology Ltd (ASX PBT: NASDAQ PRAN) has today announced Chief Medical Officer Dr. David Stamler will be presenting at the B. Riley FBR China Healthcare Investment & Partnering Symposium (CHIPS) on Saturday 17 March 2018 at 9.30am China Standard Time.

CHIPS is focused on building cross-border relationships between Chinese and Western Healthcare investors and companies. Approximately 1000 Chinese healthcare and strategic partners and investors will be in Hangzhou for the conference. Dr. Stamler and CEO Geoffrey Kempler, will also meet with investors throughout the week.

A live audio webcast of the presentation and subsequent replay may be accessed by visiting Prana's website . The webcast will be available shortly after conclusion of the presentation and archived on the Company's website for 90 days following the presentation.

Dr. Stamler joined Prana in May 2017 as its Chief Medical Officer and Senior Vice President, Clinical Development. Prior to joining Prana, Dr. Stamler served as Therapeutic Area Head, Movement Disorders for Teva Pharmaceuticals (NYSE TEVA) following Teva's US$3.5 billion acquisition of Auspex Pharmaceuticals. Dr Stamler has deep drug development experience having led two neurological agents through the approval process with the FDA.

Prana Biotechnology is developing first-in-class therapies to treat orphan and non-orphan neurological diseases. Prana's lead program, PBT434, is the first of a new generation of small molecules designed to block iron-mediated accumulation and aggregation of alpha-synuclein, an abundant brain protein widely believed to be involved in the pathogenesis of Parkinson's disease and related disorders.

PBT434 blocks the formation of toxic forms of alpha-synuclein, thus preventing the downstream effects that lead to cellular dysfunction and death. There is evidence in several animal models of disease that PBT434 prevents neuronal loss and improves motor and/or cognitive impairments. Based on this evidence and completed non-clinical studies, Prana is preparing for a first in-human study in 2018.

Prana also has a research collaboration with Takeda Pharmaceuticals International which covers the study of PBT434's ability to prevent neurodegeneration in the gastrointestinal system - an important non-motor feature - often presenting early as severe disabling impairment as part of Parkinson's disease. The partnership follows the recently publicised results that demonstrate a significant reduction of alpha-synuclein in various pre-clinical models of Parkinson's disease.

Contacts:

Investor Relations
Rebecca Wilson
E: rwilson@we-worldwide.com.au
Tp: +61 47 382 391

Media
Scott Newstead
E: snewstead@buchanwe.com.au
Tp: +61 3 9866 4722

For further information please visit the Company's web site at www.pranabio.com.

Forward Looking Statements

This press release contains "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934. The Company has tried to identify such forward-looking statements by use of such words as "expects," "intends," "hopes," "anticipates," "believes," "could," "may," "evidences" and "estimates," and other similar expressions, but these words are not the exclusive means of identifying such statements. Such statements include, but are not limited to any statements relating to the Company's drug development program, including, but not limited to the initiation, progress and outcomes of clinical trials of the Company's drug development program, including, but not limited to, PBT2, and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to the difficulties or delays in financing, development, testing, regulatory approval, production and marketing of the Company's drug components, including, but not limited to, PBT2, the ability of the Company to procure additional future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company's drug compounds, including, but not limited to, PBT2, that could slow or prevent products coming to market, the uncertainty of patent protection for the Company's intellectual property or trade secrets, including, but not limited to, the intellectual property relating to PBT2, and other risks detailed from time to time in the filings the Company makes with Securities and Exchange Commission including its annual reports on Form 20-F and its reports on Form 6-K. Such statements are based on management's current expectations, but actual results may differ materially due to various factions including those risks and uncertainties mentioned or referred to in this press release. Accordingly, you should not rely on those forward-looking statements as a prediction of actual future results.